Lenalidomide Sandoz 5 Mg Hard Capsules

Lenalidomide, the active ingredient in Lenalidomide Sandoz 5 Mg Hard Capsules, is an immunomodulatory drug (IMiD) presented as a 5 mg hard capsule for oral use. It treats multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Sandoz 5 Mg Hard Capsules as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

- Multiple Myeloma: improves progression‑free survival and overall response when combined with dexamethasone or other agents. - Myelodysplastic Syndromes (with del(5q) abnormality): reduces transfusion dependence and can induce cytogenetic remission. - Mantle Cell Lymphoma: enhances response rates in relapsed or refractory disease when used with rituximab.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools. - Rash: skin redness or itching.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low white‑blood‑cell count increasing infection risk. - Secondary primary malignancies: development of new cancers during treatment.

Before initiating therapy, clinicians should consider several safety measures.

- Pregnancy: contraindicated; teratogenic risk (Category X) – avoid use in pregnant women. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Renal impairment: use caution and monitor renal function closely. - Hepatic impairment: monitor liver function tests regularly. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Lenalidomide can interact with several drug classes; careful review is required.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (warfarin, DOACs): increased risk of thromboembolic events when combined. - Live vaccines: immunosuppression may diminish vaccine efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide levels. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity. - NSAIDs: may increase risk of renal impairment.